Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
Key Financial Performance
Fourth Quarter Revenues $225 million, Core revenue down 290 basis points year-over-year due to foreign currency and discontinued products, which were a headwind of 190 basis points.
Food Safety Segment Revenues $162 million, down 3% year-over-year, Core revenue declined 1.3%. Growth in biosecurity and pathogen detection products offset by declines in sample collection and Petrifilm.
Animal Safety Segment Revenues $64 million, Core revenue declined 6.7% year-over-year. Growth in small animal supplements and rodenticides offset by declines in other major products.
Genomics Core Revenue Declined low single digits year-over-year. Sequential improvement due to refocusing on attractive end markets.
Gross Margin 41.2%, impacted by lower volume, elevated inventory write-offs, production inefficiencies, and tariff impacts.
Adjusted EBITDA $41 million, margin of 18%, negatively impacted by inventory write-offs, tariffs, and production inefficiencies.
Adjusted Net Income $11 million, down from $22 million year-over-year, due to lower adjusted EBITDA.
Adjusted Earnings Per Share $0.05, down from $0.10 year-over-year, primarily due to lower adjusted EBITDA.
Goodwill Impairment $598 million noncash charge due to weakened end market conditions, global trade impacts, and production execution issues.
Free Cash Flow Roughly breakeven, improved $14 million sequentially but lower than anticipated due to lower EBITDA and timing of CapEx.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of Listeria Right Now: Neogen announced the launch of Listeria Right Now for use on its MDS platform for pathogens. This system provides fast detection of environmental pathogens in up to 96 samples per cycle, utilizing loop-mediated isothermal amplification.
Petrifilm Facility Progress: The new Petrifilm facility is progressing well, with initial testing production expected to begin in a few months. Once fully operational, it is expected to improve gross margins slightly compared to current production methods.
Food Safety Market Conditions: The Food Safety market is experiencing slower growth due to cumulative inflation and reduced production volumes among food producers. Regulatory cuts at USDA and FDA have impacted certain areas, but food safety testing remains a priority.
Animal Safety Market Challenges: The Animal Safety market is in a cyclical trough, with the cattle herd at a 70-year low. Veterinary distributors and ag retailers are cautious due to broader market uncertainty.
Sample Collection Production Challenges: Production inefficiencies in sample collection have led to high costs and manual labor reliance. Efforts are underway to address these issues, including potential involvement of global manufacturing partners.
Inventory Planning Improvements: Neogen is implementing more robust inventory planning and coordination to reduce elevated inventory write-offs and improve operational efficiency.
Divestiture of Non-Core Businesses: Neogen is divesting its genomics business and recently completed the divestiture of its cleaners and disinfectants business to simplify operations and focus on core areas.
Targeted Improvement Plan: A near-term blueprint has been released to manage the transition period, focusing on building a more profitable and focused Neogen.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
End Market Conditions: Worsened conditions in the Food Safety segment due to cumulative inflation over the last 4 years, leading to year-over-year declines in production volumes for food producers. This trend is not expected to reverse meaningfully in the near future.
Regulatory Environment: Cuts at USDA and FDA have impacted areas like avian flu testing and local food assistance programs, though food safety testing remains a priority. Uncertainty exists around the implementation of new Salmonella frameworks.
Animal Safety Segment: The cattle herd size, a key driver for the segment, is at a 70-year low, leading to a cyclical trough in the market. Veterinary distributors and ag retailers are cautious due to broader market uncertainty.
Global Trade Environment: Uncertainty in global trade, particularly with China, has impacted food producers' import/export planning and distributors' purchase decisions. Tariffs are expected to have a $10 million annualized impact.
Sample Collection Production: Significant inefficiencies in production due to aging equipment and reliance on manual processes, leading to high costs, excessive scrap rates, and inconsistent output.
Integration of 3M Food Safety Business: Execution shortfalls in the integration process have been exacerbated by soft market conditions, foreign currency headwinds, and global trade challenges.
Inventory Management: Elevated inventory write-offs and inefficiencies in inventory planning have negatively impacted gross margins and adjusted EBITDA.
Petrifilm Production: Challenges in transitioning production to a new facility, with potential impacts on overhead absorption rates and gross margins.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue for fiscal year 2026 is expected to be between $820 million and $840 million, excluding the revenue from the divested cleaners and disinfectants business.
Adjusted EBITDA Projections: Adjusted EBITDA is projected to range between $165 million and $175 million for fiscal year 2026, excluding the impact of the divested cleaners and disinfectants business.
Gross Margin Outlook: Gross margin in fiscal 2026 is expected to benefit from lower inventory write-offs but will face headwinds from sample collection inefficiencies and tariffs. Higher adjusted EBITDA margins are anticipated in the second half of the year due to improvements and seasonality.
Capital Expenditures: Capital expenditures are expected to decline significantly to approximately $50 million in fiscal 2026, compared to fiscal 2025.
Free Cash Flow: Free cash flow is expected to be positive in fiscal 2026, supported by reduced capital expenditures.
Market Conditions: The company does not anticipate meaningful improvement in end market conditions for fiscal 2026, with continued pressure from elevated inflation and weak food production levels. The Animal Safety market is expected to remain in a cyclical trough.
Trade Environment: The global trade environment is expected to remain dynamic, with an annualized tariff impact estimated at $10 million.
Production and Efficiency Improvements: The company plans to address inefficiencies in sample collection production and expects gradual improvements over the coming quarters. The new Petrifilm facility is expected to begin initial testing production in a few months, with full production anticipated to improve gross margins slightly.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is this the right time to put out guidance with Mike as the new CEO, and how much prudence is built into the numbers?
A:David Naemura explained that the company aims to provide clarity on the year's direction and is operating as usual. He emphasized that the guidance does not place Mike in an extraordinary position.
Q:How much of a headwind is built for next year due to the $10 million annualized tariff impact?
A:David Naemura confirmed that the $10 million is the headwind for fiscal '26 and noted that it was an increase from previous estimates.
Q:How does the company plan to address the consumer backdrop pressure and grow above the market?
A:David Naemura mentioned cautious volume growth due to inefficiencies and regulatory opportunities. John Adent added that regulatory tailwinds, such as increased pathogen testing by FDA and USDA, and the development of robust programs for Salmonella, will help the company grow.
Q:What are the key KPIs for the Petrifilm transition, and what should investors focus on?
A:David Naemura highlighted a significant reduction in capital expenditures and milestones like starting test production and certifying 17 SKUs over 4-5 quarters.
Q:Are macroeconomic conditions worsening sequentially, and what is the outlook for food safety testing growth?
A:David Naemura noted a softening macro environment and sequential declines in food production levels. He stated that food safety testing grows even when production is negative but at a lower rate, estimating low single-digit growth for the year.
Q:Can you provide sequential guidance on margins and the impact of tariffs, OpEx, and inventory management?
A:David Naemura explained that Q1 is typically the lowest quarter due to volumes and headwinds like sample collection inefficiencies. Gradual improvement is expected throughout the year, with some seasonality changes due to divestitures.
Q:What is the impact of divestitures on OpEx and stranded costs?
A:David Naemura stated that most costs are direct and go with the divested businesses. About $1.5-$2 million in additional costs will remain temporarily due to TSA arrangements, but these will reduce over time.
Q:What are the key differences in management styles between Mike and John, and what are Mike's priorities?
A:David Naemura mentioned that Mike has not started yet but described him as a back-to-basics leader. More details will be shared in the coming quarters.
Q:Is the genomics business stabilizing for fiscal '26, and what is the demand outlook for different species?
A:David Naemura noted a restructuring to focus on cattle end markets, leading to a slight revenue decline in fiscal '26 compared to fiscal '25. The majority of the business is focused on cattle.
Q:What has driven strength in the food quality pathogen product lines?
A:John Adent attributed growth to investments in pathogen testing, including new product launches like the MDS quant Salmonella and Listeria tests, which address unmet needs.
Q:Why is the CapEx for 2026 lower than expected?
A:David Naemura explained that some CapEx was pulled forward into '25, and the company is prioritizing plant-related work, resulting in a step-down in CapEx.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the differences in management styles between Mike and John, as Mike has not started yet. Additionally, there was limited detail on the sequential guidance for margins and the specific impacts of tariffs, OpEx, and inventory management.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Animal Safety
FSIS
Food Safety
LLC
MDS
Petrifilm
Research Division
USDA
action
assessment
basis
condition
core
decline
digit
end market
environment
facility
food safety
framework
improvement
inefficiency
inventory write
level
pathogen
policy plan
producer
product category
product line
production
rate
safety policy
sample collection
segment
tariff
testing
write offs
NEOG Transcript
Neogen Corporation (NEOG) Q3 2026 Earnings Call Transcript
Positive4-9
The company reported a strong financial performance with a 10% YoY revenue increase, improved gross margins, and a 15% rise in net income. EPS also rose, indicating enhanced profitability. Despite increased operating expenses due to R&D and marketing, the overall financial health appears robust. The raised revenue guidance further supports a positive outlook. However, the lack of details on strategic initiatives and operational updates, along with risks mentioned in forward-looking statements, tempers the sentiment slightly. Given the market cap, a positive stock price movement of 2% to 8% is expected.
Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript
Unknown10-9
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript
Unknown7-29
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
NEOG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
